SEC Form 4 · accession 0001610717-26-000421
10x Genomics, Inc. · TXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Serge Saxonov
Officer — Chief Executive Officer · Director
Period of report
Sep 22, 2026
Accepted (ET)
Sep 24, 2026 · 4:29 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001770787
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Sep 22, 2026 | S | 1,000 | $78.2284 | D | 1,074,249 | D | |
| Class A Common StockF3 | Sep 22, 2026 | S | 2,000 | $79.6195 | D | 1,072,249 | D | |
| Class A Common StockF4 | Sep 22, 2026 | S | 9,300 | $80.9033 | D | 1,062,949 | D | |
| Class A Common StockF5 | Sep 22, 2026 | S | 9,900 | $81.8254 | D | 1,053,049 | D | |
| Class A Common StockF6 | Sep 22, 2026 | S | 2,800 | $82.365 | D | 1,050,249 | D | |
| Class A Common StockF7 | holding | — | — | — | 27 | I | See footnote | |
| Class A Common StockF8 | holding | — | — | — | 213,250 | I | See footnote | |
| Class A Common StockF9 | holding | — | — | — | 71,644 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F7The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
- F8The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
- F9The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.